Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease (NAFLD) in Non-Obese Patients with Schizophrenia: A Retrospective Study
Wenying Yi,Haibo Wu,Weibin Fu,Huimei Feng,Jie Huang,Haijing Li,Zhen Song,Yuwei Chen,Yingjun Zheng,Shenglin She
DOI: https://doi.org/10.2147/dmso.s437811
2024-02-20
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Wenying Yi, 1, 2 Haibo Wu, 1, 2 Weibin Fu, 1, 2 Huimei Feng, 1, 2 Jie Huang, 1, 2 Haijing Li, 1, 2 Zhen Song, 1, 2 Yuwei Chen, 1, 2 Yingjun Zheng, 1, 2 Shenglin She 1, 2 1 Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 2 Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China Guangzhou Medical University, Guangzhou, People's Republic of China Correspondence: Shenglin She, Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou MedicalUniversity, No. 36 Mingxin Road, Liwan District, Guangzhou, People's Republic of China, Tel +86-13825154669, Fax +86-20-82068107, Email Background: To assess the prevalence and risk factors of NAFLD in non-obese patients with schizophrenia in a public psychiatric hospital in China. Methods: A total of 1,305 adult inpatients with schizophrenia in 2019 were included in this retrospective study. Body mass index (BMI) ≥ 25 kg/m 2 was considered obese, and BMI < 25 kg/m 2 was considered non-obese. We obtained the data from electronic records of the Affiliated Brain Hospital of Guangzhou Medical University. Results: A total of 1,045 non-obese patients and 260 obese patients were included in this study. The prevalence of NAFLD in non-obese patients was 25.0%, and it was much lower that in the obese patients (25.0% vs 64.6%, p < 0.001). Among the non-obese patients, there were significant differences in age, BMI, alanine aminotransferase (ALT), metabolic indices, and the prevalence of diabetes and hypertension between patients with NAFLD and patients without NAFLD. According to the results of binary logistic regression analysis, age, BMI, ALT, triglyceride (TG) and diabetes were significantly related to NAFLD among non-obese patients with schizophrenia. In contrast, HDL-C was was negatively associated with NAFLD among non-obese patients. Conclusion: This study suggested that NAFLD was common in patients with schizophrenia, even in non-obese patients with schizophrenia. In non-obese patients with schizophrenia, age, BMI, ALT, TG and diabetes are significantly associated with NAFLD. Moreover, HDL-C level was an independent protective factor against NAFLD. Given the adverse outcomes of NAFLD, it is necessary to increase awareness of NAFLD in patients with schizophrenia, especially in non-obese patients with schizophrenia. Keywords: schizophrenia, NAFLD, non-obese, obese, risk factors, China NAFLD is a prevalent chronic liver disease worldwide, with an estimated global prevalence at 29.8%. 1 NAFLD is positively associated with the risk of extra-hepatic tumors, cardiovascular disease, diabetes and metabolic syndrome. 2 Compared with patients without NAFLD, patients with NAFLD have an increased risk of all-cause mortality. 3 The number of deaths caused by NAFLD has significantly increased to 168,970 in 2019 since 1990. 4 Obesity is associated with a 3.5 times higher risk of NAFLD, and BMI is significantly associated the risk of developing NAFLD. 5 Although NAFLD is more prevalent in obese subjects, it is also common in non-obese individuals. A meta-analysis reported that in the general population, the frequency of NAFLD ranges from 25% to higher than 50%, and approximately 40% of subjects with NAFLD worldwide can be classified as non-obese. 6 Compared to obese patients with NAFLD, non-obese individuals with NAFLD had less severe metabolic profiles, while evidence found that non-obese individuals with NAFLD also had increased all-cause mortality and substantial comorbidities, including hypertension, diabetes, cardiovascular disease. 6 Schizophrenia is a common and severe mental disorder. People with schizophrenia have shorter lifespans (by 15–20 years) and higher all-cause mortality rates. 7 Diabetes and cardio-cerebrovascular system disorders are attributed to the higher mortality rates in schizophrenia. 7 It is widely reported that patients with schizophrenia have higher risk to experience obesity and metabolic abnormalities, which are closely associated with diabetes and cardio-cerebrovascular system disorders. 8 Regardless of the diagnostic criteria of metabolic syndrome, the prevalence of metabolic syndrome in patients with schizophrenia was higher than that in the health controls. 9 However, only a minority of patients with schizophrenia pay attention to balanced diet and physical exercise.<sup -Abstract Truncated-
endocrinology & metabolism